122 related articles for article (PubMed ID: 19403757)
1. A mutation in helicase motif IV of herpes simplex virus type 1 UL5 that results in reduced growth in vitro and lower virulence in a murine infection model is related to the predicted helicase structure.
Biswas S; Miguel RN; Sukla S; Field HJ
J Gen Virol; 2009 Aug; 90(Pt 8):1937-1942. PubMed ID: 19403757
[TBL] [Abstract][Full Text] [Related]
2. Mutations close to functional motif IV in HSV-1 UL5 helicase that confer resistance to HSV helicase-primase inhibitors, variously affect virus growth rate and pathogenicity.
Biswas S; Tiley LS; Zimmermann H; Birkmann A; Field HJ
Antiviral Res; 2008 Oct; 80(1):81-5. PubMed ID: 18539344
[TBL] [Abstract][Full Text] [Related]
3. A single drug-resistance mutation in HSV-1 UL52 primase points to a difference between two helicase-primase inhibitors in their mode of interaction with the antiviral target.
Biswas S; Kleymann G; Swift M; Tiley LS; Lyall J; Aguirre-Hernández J; Field HJ
J Antimicrob Chemother; 2008 May; 61(5):1044-7. PubMed ID: 18299638
[TBL] [Abstract][Full Text] [Related]
4. Single amino acid substitutions in the HSV-1 helicase protein that confer resistance to the helicase-primase inhibitor BAY 57-1293 are associated with increased or decreased virus growth characteristics in tissue culture.
Biswas S; Jennens L; Field HJ
Arch Virol; 2007; 152(8):1489-500. PubMed ID: 17404685
[TBL] [Abstract][Full Text] [Related]
5. Characteristics of Helicase-Primase Inhibitor Amenamevir-Resistant Herpes Simplex Virus.
Sato Y; Suenaga T; Kobayashi M; Miyazaki N; Suzuki T; Ishioka K; Suzutani T
Antimicrob Agents Chemother; 2021 Sep; 65(10):e0049421. PubMed ID: 34228537
[TBL] [Abstract][Full Text] [Related]
6. Characterization of virus strains resistant to the herpes virus helicase-primase inhibitor ASP2151 (Amenamevir).
Chono K; Katsumata K; Kontani T; Shiraki K; Suzuki H
Biochem Pharmacol; 2012 Aug; 84(4):459-67. PubMed ID: 22687623
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of herpes simplex virus replication by a 2-amino thiazole via interactions with the helicase component of the UL5-UL8-UL52 complex.
Spector FC; Liang L; Giordano H; Sivaraja M; Peterson MG
J Virol; 1998 Sep; 72(9):6979-87. PubMed ID: 9696789
[TBL] [Abstract][Full Text] [Related]
8. Effects of therapy using a helicase-primase inhibitor (HPI) in mice infected with deliberate mixtures of wild-type HSV-1 and an HPI-resistant UL5 mutant.
Sukla S; Biswas S; Birkmann A; Lischka P; Ruebsamen-Schaeff H; Zimmermann H; Field HJ
Antiviral Res; 2010 Jul; 87(1):67-73. PubMed ID: 20420855
[TBL] [Abstract][Full Text] [Related]
9. A mutation in the human herpes simplex virus type 1 UL52 zinc finger motif results in defective primase activity but can recruit viral polymerase and support viral replication efficiently.
Chen Y; Livingston CM; Carrington-Lawrence SD; Bai P; Weller SK
J Virol; 2007 Aug; 81(16):8742-51. PubMed ID: 17553899
[TBL] [Abstract][Full Text] [Related]
10. UL52 primase interactions in the herpes simplex virus 1 helicase-primase are affected by antiviral compounds and mutations causing drug resistance.
Muylaert I; Zhao Z; Elias P
J Biol Chem; 2014 Nov; 289(47):32583-92. PubMed ID: 25278021
[TBL] [Abstract][Full Text] [Related]
11. The three-component helicase/primase complex of herpes simplex virus-1.
Bermek O; Williams RS
Open Biol; 2021 Jun; 11(6):210011. PubMed ID: 34102080
[TBL] [Abstract][Full Text] [Related]
12. Mismatch primer-based PCR reveals that helicase-primase inhibitor resistance mutations pre-exist in herpes simplex virus type 1 clinical isolates and are not induced during incubation with the inhibitor.
Sukla S; Biswas S; Birkmann A; Lischka P; Zimmermann H; Field HJ
J Antimicrob Chemother; 2010 Jul; 65(7):1347-52. PubMed ID: 20453068
[TBL] [Abstract][Full Text] [Related]
13. Replacement of gly815 in helicase motif V alters the single-stranded DNA-dependent ATPase activity of the herpes simplex virus type 1 helicase-primase.
Graves-Woodward KL; Weller SK
J Biol Chem; 1996 Jun; 271(23):13629-35. PubMed ID: 8662872
[TBL] [Abstract][Full Text] [Related]
14. Isolation and characterization of herpes simplex virus type 1 resistant to aminothiazolylphenyl-based inhibitors of the viral helicase-primase.
Liuzzi M; Kibler P; Bousquet C; Harji F; Bolger G; Garneau M; Lapeyre N; McCollum RS; Faucher AM; Simoneau B; Cordingley MG
Antiviral Res; 2004 Dec; 64(3):161-70. PubMed ID: 15550269
[TBL] [Abstract][Full Text] [Related]
15. Detection of HSV-1 variants highly resistant to the helicase-primase inhibitor BAY 57-1293 at high frequency in 2 of 10 recent clinical isolates of HSV-1.
Biswas S; Smith C; Field HJ
J Antimicrob Chemother; 2007 Aug; 60(2):274-9. PubMed ID: 17550887
[TBL] [Abstract][Full Text] [Related]
16. Two-hybrid analysis of the interaction between the UL52 and UL8 subunits of the herpes simplex virus type 1 helicase-primase.
Constantin N; Dodson MS
J Gen Virol; 1999 Sep; 80 ( Pt 9)():2411-2415. PubMed ID: 10501495
[TBL] [Abstract][Full Text] [Related]
17. High conservation of herpes simplex virus UL5/UL52 helicase-primase complex in the era of new antiviral therapies.
Collot M; Rouard C; Brunet C; Agut H; Boutolleau D; Burrel S
Antiviral Res; 2016 Apr; 128():1-6. PubMed ID: 26826441
[TBL] [Abstract][Full Text] [Related]
18. Helicase-primase complex of herpes simplex virus type 1: a mutation in the UL52 subunit abolishes primase activity.
Klinedinst DK; Challberg MD
J Virol; 1994 Jun; 68(6):3693-701. PubMed ID: 8189507
[TBL] [Abstract][Full Text] [Related]
19. Recruitment of polymerase to herpes simplex virus type 1 replication foci in cells expressing mutant primase (UL52) proteins.
Carrington-Lawrence SD; Weller SK
J Virol; 2003 Apr; 77(7):4237-47. PubMed ID: 12634381
[TBL] [Abstract][Full Text] [Related]
20. Roles of the Phosphorylation of Herpes Simplex Virus 1 UL51 at a Specific Site in Viral Replication and Pathogenicity.
Kato A; Oda S; Watanabe M; Oyama M; Kozuka-Hata H; Koyanagi N; Maruzuru Y; Arii J; Kawaguchi Y
J Virol; 2018 Sep; 92(18):. PubMed ID: 29976672
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
